Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel...
Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel...
Growth investors willing to take the risk to shoot for the moon find prime targets...
The more prevalent role that algorithms, automation and data have on our day to day...
Amgen's never moved faster. In late August of last year, the first patient enrolled in...
It’s not surprising that Steven Yatomi-Clarke started his second career at a company named Prescient...
The nation's youngest cancer patients have been given new hope, with a cutting-edge treatment being...
Over the last decade, technological improvements and algorithmic learning have made rapid improvements to many...
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of...
On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of...
Highlights: Innovative ‘basket’ study design will assess drug in multiple cancers Precision medicine approach offers...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.